Apollomics Inc.

APLM | $0.47 -1.05% -1.06% 140K

(0.0% 1d) (-18.7% 1m) (-88.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-73.28% volume)
Earnings Calendar:
Market Cap: $ 42,063,021

Sec Filling | Patents | 3 employees

formerly known as cbt pharmaceuticals. at apollomics, we are a purpose driven company imagining a world without cancer. we let science drive our decision making to advance our programs. we believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. apollomics is committed to the discovery and development of oncology combination therapies. we believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. we have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. when developing an asset, we begin with rigorous ind-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. this path may be as a monotherapy, a combination therapy, or both. while our ultimate goal is to study each of our assets in combination with other agents, we h

ycombinator

add to watch list Paper trade email alert is off

Press-releases

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -17.25% | O: -2.99% H: 6.9% C: 0.0%
association cancer research for meeting

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -29.96% | O: 5.51% H: 0.0% C: -5.08%
association cancer research meeting

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -22.31% | O: -0.83% H: 25.0% C: 25.0%
year financial results

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -18.69% | O: -1.38% H: 7.35% C: 1.74%
conference year financial results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -38.16% | O: -7.89% H: 15.0% C: 9.86%
financial

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-07 (Crawled : 12:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| -19.15% | O: 6.23% H: 6.88% C: 6.69%
conference life sciences

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published: 2024-01-19 (Crawled : 21:00) - globenewswire.com
APLM | $0.47 -1.05% -1.06% 140K

n/a

| Email alert Add to watchlist
nasdaq